Vistagen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vistagen Therapeutics, Inc. on June 6, 2023. The report details a material modification to the rights of security holders regarding the company's capital structure.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure changes.
Material Changes
- Reverse Stock Split: The Company implemented a 1-for-30 reverse split of its Common Stock, effective June 6, 2023.
- Share Consolidation: Every 30 shares of Common Stock outstanding prior to the effective time were consolidated into one share.
- Fractional Shares: No fractional shares were issued; fractional amounts were rounded up to the nearest whole share.
- Trading Details: Post-split trading began on June 7, 2023, under CUSIP number 92840H 400 on the Nasdaq Capital Market.
- Authorized Shares: The number of authorized Common Stock shares remains at 325,000,000, and Preferred Stock remains at 10,000,000.
- Par Value: The par value per share for both Common and Preferred Stock remains unchanged at $0.001.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the structural change. The reverse split was unanimously approved by the Board of Directors and previously authorized by stockholders at the 2022 Annual Meeting.
Investor Verification Checklist
- Verify the new CUSIP number (92840H 400) for post-split trading.
- Confirm the adjusted share count in brokerage accounts following the 1-for-30 consolidation.
- Review the attached Certificate of Amendment (Exhibit 3.1) for full legal details of the Charter Amendment.
- Check the press release (Exhibit 99.1) for any additional context regarding the rationale for the split.